Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Tianshuping (olmesartan medoxomil + amlodipine) in essential hypertension
ChiCTR2100048938Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of olmesartan medoxomil + amlodipine in essential hypertension, sponsored by West China Hospital of Sichuan University. Primary endpoint: 24-hour average systolic blood pressure. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
olmesartan medoxomil + amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2100048938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048938.